$70.82
-3.58-4.81%
Benzinga
Benzinga
Benzinga
수요일, 10월 14
Benzinga
© 2026 Benzinga | All Rights Reserved
Tarsus Pharmaceuticals (TARS) earnings history, EPS estimates, revenue forecasts and company guidance.
Earnings Per Share (Non-GAAP)
Quarterly Revenue (Billions)
| Metric | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 |
|---|---|---|---|---|
| Earnings Per Share (Non-GAAP) | ||||
| Estimate | $-0.25 | $-0.39 | $-0.07 | $-0.34 |
| Actual | $-0.43 | $-0.16 | $-0.20 | $-0.30 |
| Surprise | -72.0% | +59.0% | -185.7% | +11.8% |
| Revenue | ||||
| Estimate | $167.2M | $149.8M | $144.7M | $115.3M |
| Actual | $173.9M | $162.1M | $151.7M | $118.7M |
| Surprise | +4.00% | +8.18% | +4.80% | +2.93% |
| Metric | Q3 '26E | Q4 '26E | Q1 '27E | Q2 '27E |
|---|---|---|---|---|
| Earnings Per Share (Non-GAAP) | ||||
| Consensus | $-1.71 | $-3.40 | $-0.69 | $-0.37 |
| Revenue | ||||
| Consensus | $183.9M | $201.2M | — | — |
| 회계 분기 | 보고된 날짜 | 실제 EPS | 예상 EPS | 놀라다 % |
|---|---|---|---|---|
| Q2 | Aug 6, 2026 | $-0.43 | $-0.25 | -72.0 % |
| Q1 | May 6, 2026 | $-0.16 | $-0.39 | 59.0 % |
| Q4 | Feb 23, 2026 | $-0.20 | $-0.07 | -185.7 % |
| Q3 | Nov 4, 2025 | $-0.30 | $-0.34 | 11.8 % |
| 회계 분기 | 보고된 날짜 | 실제 수익 | 예상 수익 | 놀라다 % |
|---|---|---|---|---|
| Q2 | Aug 6, 2026 | $173.91M | $167.22M | 4.00 % |
| Q1 | May 6, 2026 | $162.05M | $149.80M | 8.18 % |
| Q4 | Feb 23, 2026 | $151.67M | $144.72M | 4.80 % |
| Q3 | Nov 4, 2025 | $118.70M | $115.32M | 2.93 % |